Post-Notice of Compliance (NOC) Changes: Safety and Efficacy Document

This guidance document applies to sponsors intending to make changes to new drugs that have received a NOC pursuant to section C.08.004 of the Food and Drug Regulations. These new drugs may include pharmaceuticals, biologics, and radiopharmaceuticals for human use and pharmaceutical and certain biotechnological products for veterinary use, including those submissions for which a NOC has been recommended but issuance of the NOC has been placed on hold.

Publisher

Health Canada

Resources

2

Catalogue metadata updated

2021-07-07